CoChat

Aripiprazole Augmentation of Selective Serotonin Reuptake Inhibitors for Treatment-Resistant Major Depressive Disorder

Papakostas, George I., Petersen, Timothy J., Kinrys, Gustavo, Burns, Alana M., Worthington, John J., Alpert, Jonathan E., Fava, Maurizio, Nierenberg, Andrew A. · 2005 · The Journal of Clinical Psychiatry
Cited by 125

The DOI matches its Crossref record.

Abstract

BACKGROUND: Due to their favorable side effect profile, atypical antipsychotic agents offer important therapeutic advantages in mood disorders. Aripiprazole, an atypical antipsychotic agent with partial dopaminergic and serotonin 1A receptor agonist activity, may be particularly useful when used in conjunction with standard antidepressants in treatment-resistant depression. The purpose of this study was to test this hypothesis in depressed outpatients who have not experienced significant clinical improvement following an adequate trial of a selective serotonin reuptake inhibitor (SSRI). METHOD: 12 patients (mean +/- SD age = 46.6 +/- 11.3 years, 66.7% female) with major depressive disorder (MDD) diagnosed by use of the Structured Clinical Interview for DSM-IV-Axis I Disorders, who had failed to experience a clinical response following an adequate trial of an SSRI, were treated with open-label aripiprazole in addition to their SSRI for 8 weeks. Clinical response was defined as a 50% or greater decrease in depressive symptoms during the course of the trial (baseline-endpoint) as measured by the 17-item Hamilton Rating Scale for Depression total score. Data were collected from August 2003 to July 2004. RESULTS: 9/12 (75.0%) patients completed the trial. Using a completer analysis, 5/9 (55.6%) patients were classified as responders. An intent-to-treat (ITT) analysis resulted in 7 responders (58.3%). The overall proportion of remitters was 3/9 (33.3%) using a completer analysis and 5/12 (41.7%) using the ITT analysis. Aripiprazole administration appeared safe, with no severe adverse events observed in any of the study participants. CONCLUSIONS: These results suggest a possible augmentation role for aripiprazole when used in conjunction with SSRIs in SSRI-resistant MDD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.4088/jcp.v66n1017

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 125

Metadata

Authors
Papakostas, G. I., Petersen, T. J., Kinrys, G., Burns, A. M., Worthington, J. J., Alpert, J. E., Fava, M., & Nierenberg, A. A.
Venue
The Journal of Clinical Psychiatry
Published
2005-10-15
Volume
66
Issue
10
Pages
1326-1330
ISSN
0160-6689 (ISSN-L)
OpenAlex
W2064002445
Cited by
125
References
0
FWCI
11.66
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Aripiprazole Augmentation of Selective Serotonin Reuptake Inhibitors for Treatment-Resistant Major Depressive Disorder. https://app.cochat.ai/papers/10.4088/jcp.v66n1017
The paper
Papakostas, G. I., Petersen, T. J., Kinrys, G., Burns, A. M., Worthington, J. J., Alpert, J. E., Fava, M., & Nierenberg, A. A. (2005). Aripiprazole Augmentation of Selective Serotonin Reuptake Inhibitors for Treatment-Resistant Major Depressive Disorder. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.v66n1017

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.